Green Cross Corporation, founded in 2000 and headquartered in South Korea, is a leading biopharmaceutical company focused on developing innovative treatments for hemophilia and other rare diseases. The company specializes in producing plasma-derived therapeutics and recombinant protein products, positioning itself as a key player in the global healthcare sector.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| SANGA 4.29% 2027-02-22 KRWGreen Cross Corporation | South Korea | 2027-02-22 | 4.288 | 3.24 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Since its first bond issuance in 2010, Green Cross Corporation has actively utilized the debt market to fund its research and development initiatives. Notably, in 2021, the company issued a significant $300 million bond to support its expansion into new therapeutic areas, achieving yields that are competitive within the biopharmaceutical industry. The bonds feature a unique convertible option, allowing investors to convert their holdings into equity at a predetermined rate, reflecting the company's commitment to fostering investor confidence and participation in its growth trajectory.